(Press-News.org) ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that rheumatoid arthritis (RA) patients in sustained remission who stopped TNF inhibitors (TNFi) had significantly more flares and lower Boolean 2.0 remission rates compared with those who continued treatment. Boolean 2.0 is a revised definition for evaluating disease activity in RA that classifies more patients as achieving remission than Boolean 1.0. It is endorsed by the American College of Rheumatology and the European Alliance for Associations in Rheumatology (EULAR) (Abstract #L07).
As more RA patients achieve sustained remission, questions remain about the long-term effectiveness of tapering and stopping treatment with TNFi. In the randomized, multicenter, non-inferiority ARCTIC REWIND trial, Siri Lillegraven, MD, MPH, PhD at Diakonhjemmet Hospital, Oslo, Norway, and colleagues compared the three-year effect of tapered versus stable treatment on RA patients in sustained remission. It follows a previous year-long trial.
The current trial included 92 patients from Norwegian rheumatology centers who were randomized 1:1 to taper TNF inhibitors to withdrawal or continue treatment. All had study visits every four months throughout the three-year study period. Patients restarted full-dose therapy if they experienced a flare, which was defined as loss of remission plus a 0.6 units or greater increase in the disease activity score and two or more swollen joints. In lieu of these criteria, a doctor and patient could agree that a significant flare had occurred. The trial also looked at remission status, medication use, and serious side effects or complications.
Of the original 92 patients, 80 (87%) completed the three-year follow-up. By the trial’s end, 75% of patients in the taper group experienced a flare versus 15% in the stable group. Most of those who flared were in remission by their next office visit (81% in the taper group and 67% in the stable group), although the taper group had significantly lower Boolean 2.0 remission rates throughout the study.
Lillegraven says the researchers were “somewhat surprised by the difference in how many patients were in ACR/EULAR Boolean remission in the two groups,” noting that “although most patients in the tapering group flared within the first year and reinstated previous full-dose treatment, Boolean 2.0 remission rates were significantly lower in the tapering TNFi group than the stable group throughout the study period.”
And, she says, “The risk difference for flares observed in these data [-24% over three years] is quite comparable to that observed in the one-year study. That is a little surprising, as we might have expected more of the patients on stable treatment to develop a flare over time, reducing the difference between the two groups.”
Lillegraven notes that the study’s open label design might influence the evaluation of flares but says study personnel were “continuously instructed about the importance of recording flares in a similar manner in both groups, a pragmatic approach that mirrors clinical care where patients know what treatment they are receiving.”
Lillegraven says her team has many studies planned to better understand how treatment for RA patients in remission can be personalized. This includes factors that would help identify which patients should and should not taper their treatment.
“We have started planning a 10-year follow-up of the study to better understand the long-term outcome of different treatment strategies in RA remission. We are [also] considering studies to better understand patient preferences with regard to medication tapering.”
Shared decision making is central to any consideration of tapering, she says.
“The patient should be informed of the risks and benefits of tapering, and the total situation of the patient should be taken into account before the decision is made. Although the data do not support tapering TNFi at a group level, factors such as adverse events related to treatment or the patient having a strong preference toward tapering will naturally influence such a decision.”
This research was supported by grants from the Research Council of Norway and the South-Eastern Norway Regional Health Authority.
###
About ACR Convergence
ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 240 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit https://rheumatology.org/annual-meeting, or join the conversation on Twitter by following the official hashtag (#ACR23).
About the American College of Rheumatology
Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit www.rheumatology.org.
END
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant (Abstract #L06).
Juvenile-onset systemic sclerosis (jSSc), also called scleroderma, is a disfiguring autoimmune disorder marked by hardening of the skin and internal organs, including the digestive tract, lungs, musculoskeletal system, kidneys and heart. The psychological and physical effects of the disease persist into adulthood, and many patients have a shortened lifespan. Effective ...
Using data from over 900 participants in a large, diverse, and national sample of Canadian adolescents and young adults from the Canadian Study of Adolescent Health Behaviors, a new study published in the journal Sexual Health researchers found significant associations between sex work and muscle dysmorphia.
Sex work, in its various forms, is highly stigmatized in Canadian society, and sex workers are often victims of harmful stereotypes. It is estimated that roughly 4% of Canadian adolescents engage in selling sex, and research has shown that those involved in sex work are more at risk to experience substance use ...
Neurodegenerative diseases like Alzheimer’s and Parkinson’s can be associated to depression and anxiety. Dr. Sabine Krabbe, a neuroscientist at DZNE’s Bonn site, is receiving 1.2 million US dollars from the Chan Zuckerberg Initiative to understand the mechanisms involved in the onset of these syndromes. To this end, she aims to examine the function of the brain’s “emotion center” using new methodologies to examine the function of single cells in experimental mouse models. The study will run for four ...
About The Study: Black women who reported experiences of interpersonal racism in situations involving employment, housing, and interactions with police appeared to have an increased risk of stroke, even after accounting for demographic and vascular risk factors, according to the results of this study including 48,000 Black women. These findings suggest that the high burden of racism experienced by Black U.S. women may contribute to racial disparities in stroke incidence.
Authors: Shanshan Sheehy, Sc.D., of Boston University, is the corresponding author.
To ...
About The Study: Maternal mRNA vaccination was associated with a lower risk of Omicron SARS-CoV-2 infection among infants up to six months of age only if the vaccine was given during the antenatal period in this study of 7,292 infants in Singapore. These findings suggest that mRNA vaccination during pregnancy may be needed for lower risk of SARS-CoV-2 infection among newborns.
Authors: Orlanda Goh, M.B., B.S., M.P.H., of Singapore General Hospital in Singapore, and Chee Fu Yung, M.B.Ch.B., of KK Women’s and Children’s ...
What can we expect in the worst-case scenario? In regions with a high risk of flooding, this is an important question: what extreme events should the protective measures be designed for? Often this is answered simply by looking at history: The worst flood events of the past decades or centuries are regarded as a realistic upper limit for what can be expected in the future.
However, this can be misleading, as so-called "mega-floods" have shown in recent years. Time and again, extreme flood events occur, extraordinary outliers that were not considered possible on the basis of local data. However, a major research project carried out under the leadership ...
“The world isn’t doing terribly well in averting global ecological collapse,” says Dr Florian Rabitz, a researcher at Kaunas University of Technology (KTU), Lithuania, the author of a new monograph Transformative Novel Technologies and Global Environmental Governance recently published by Cambridge University Press.
Greenhouse gas emissions, species extinction, ecosystem degradation, chemical pollution, and more are threatening the Earth’s future. Despite decades of international agreements and countless high-level ...
A leading researcher has been awarded a prestigious Royal Society Fellowship worth over £1.4 million to study how dryland landscapes respond to a changing climate.
Dr Monika Markowska will join Northumbria University in January 2024 as part of her Royal Society University Research Fellowship. The Royal Society is the world’s oldest independent scientific academy, bringing together many of the world’s most distinguished scientists drawn from all areas of science, engineering, and medicine.
Specialising in the variability of the Earth’s past climate, Dr Monika Markowska is an Isotope Geochemist, who is currently based at Max Planck ...
Production of biological substances for medicine using genetically engineered yeast cells shows new promising results in basic research from an international team of researchers. In 2022, the researchers attracted international attention by programming the longest-ever biosynthetic pathway - or 'assembly line' - into a microbial cell factory and designing it to produce biological substances for cancer drugs.
In an article published in the scientific journal Nature Chemical Biology, Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast, the researchers now present results with the artificial production ...
CÚRAM researchers at University of Galway, together with colleagues at the Centre for Molecular Nanometrology at University of Strathclyde have published work unveiling the inner workings of cells.
Published recently in the German scientific journal Angewandte Chemie, the work provides a deeper understanding of the way components within cells are interconnected. This research has been on the agenda of scientists worldwide for many years, and has yielded plenty of useful information on how certain diseases behave.
Through cellular visualisation using SRS microscopy, ...
